Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Aimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference


Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 11:20 a.m. E.T.

A live webcast of the fireside chat will be accessible in the Investor Relations section of the Aimmune website at www.aimmune.com. A replay will be available following the webcast.

About Aimmune

Aimmune Therapeutics, Inc. is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company's Characterized Oral Desensitization ImmunoTherapy (CODITtm) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy, a marketing authorization application under review with the European Medicines Agency (EMA) for its investigational medicine for peanut allergy, and other investigational therapies in development to treat other food allergies. For more information, please visit www.aimmune.com.


These press releases may also interest you

at 17:00
StateHouse Provides an Update on Application for Management Cease Trade Order
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols 2023 Annual Report on Form 20-F filed with the SEC
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
FDA Roundup: April 19, 2024
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor eyes SEIU-CUPE award for Ontario health care members
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...

More news about Health...


News published on and distributed by: